Guillain–Barré Syndrome, Before and After Zika

Luis Del Carpio-Orantes1 Jesús Salvador Sánchez-Díaz1

1Department of Internal Medicine and Critical Medicine, Delegation Veracruz North, Mexican Institute of Social Security, Veracruz, Mexico

Address for correspondence Luis Del Carpio-Orantes, Instituto Mexicano del Seguro Social, Alley 12 de Octubre 603, Center, Veracruz, Mexico, ZC 91900 (e-mail: neurona23@hotmail.com).

After the invasion of the Zika virus to American lands following the route of dissemination left by Chikungunya in 2015, an increase in acute neurological syndromes was noted, among them the so-called Guillain–Barré syndrome, which is characterized as the main current cause of flaccid paralysis as well as being an acute demyelinating polyneuropathy. After the outbreak of Zika in the Americas, incidences as high as 400 and 800% of the expected cases were reported, mainly in South America and the Caribbean.

Prior to this colonization by arboviruses hitherto unknown in America, Guillain–Barré syndrome was considered an entity with a low global incidence in the range of 0.6 to 4 cases per 100,000 inhabitants. It usually without distinction of gender and in two predominant age groups: 15 to 34 years and 60 to 74 years. Regarding the etiological agents, the main ones identified previously were Campylobacter jejuni (20–50%), Cytomegalovirus (5–22%), Haemophilus influenzae (2–13%), Epstein–Barr virus (10%), and Mycoplasma pneumoniae (5%). In addition to infectious agents, other related conditions are surgeries, vaccines, and injuries. The predominant neuroconduction pattern was axonal (acute motor axonal neuropathy or acute motor sensory axonal neuropathy) both in America and in Europe and some Asian regions, which conferred poor functional and vital prognosis.1-3

After the arrival of Zika and after declaring a neurotropic virus due to the high incidence of cases of microcephaly (now called congenital syndrome due to Zika) and Guillain–Barré syndrome, according to a bibliometric study, the overall incidence of these cases due to recent Zika infection (from South America to Mexico) was 42%, although the incidence of Zika was very variable even in the same geographical area, being from 0 to 100%; the estimated prevalence according to a meta-analysis was 1.23%. In contrast, the most frequent neuroconduction pattern was acute inflammatory demyelinating polyneuropathy, which, according to bibliographic records, has a better functional and vital prognosis, recovering more quickly and in many cases without sequelae (►Table 1).

In a more delimited way, in Mexico, the incidence of cases associated with Zika was very low (5.8%); in contrast, other neurotropic infectious agents were identified: dengue, chikungunya, herpes, enterovirus, hepatitis B and even more relevant, the identification of Campylobacter cases that in contrast to common campylobacteriosis, these were not always presented with diarrheal or enteral syndrome, hypothesizing that probably the neurological syndrome was the primary manifestation of this infection.

Despite all the documentary work done so far, the full causal relationship between Zika and Guillain–Barré is not clear, nor has it been possible to clarify why the incidences of the syndrome increased so exponentially in several latitudes of the American continent.4,5

Following the information obtained in a global way, the following points of good practice are recommended for a better diagnosis and treatment of patients affected by Guillain–Barré syndrome:

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Main differences of Guillain Barre syndrome, before and after zika</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before Zika</strong></td>
<td><strong>After Zika</strong></td>
</tr>
<tr>
<td><strong>Predominant neuroconduction pattern</strong></td>
<td>AMAN</td>
</tr>
<tr>
<td><strong>Etiological agents</strong></td>
<td>Campylobacter jejuni (&lt; 5%), Cytomegalovirus (&lt; 5%), Haemophilus influenzae (&lt; 5%), Epstein–Barr virus (&lt; 5%), Mycoplasma pneumoniae (&lt; 5%), Zika</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>Intravenous immunoglobulin or plasmapheresis</td>
</tr>
<tr>
<td><strong>Prognosis</strong></td>
<td>Bad, because of the predominant axonal involvement</td>
</tr>
</tbody>
</table>

Abbreviations: AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy.

©2019 Association for Helping Neurosurgical Sick People

License terms

DOI https://doi.org/10.1055/s-0039-1697564
ISSN 0976-3147.

Published online: 09.10.2019
• All acute neurological symptoms that meet the clinical criteria of Asbury–Cornblath (asymmetric paralysis and areflexia) should be treated as Guillain–Barré syndrome until proven otherwise.

• Take into account that there are atypical variants such as Miller–Fisher syndrome, pharyngo–cervical–brachial weakness, facial diplegia, Bickerstaff encephalitis, among others.

• Any case of Guillain–Barré syndrome should be protocolized according to Brighton criteria, trying to perform a diagnostic protocol that includes cerebrospinal fluid analysis, neuroimaging studies, and nerve neuroconduction.

An infectious protocol should be performed that includes viral and bacterial agents with proven neurotropism, integrating endemic or tropical zones, serologies, and molecular studies of dengue, Zika, and chikungunya. Likewise, the importance of identifying the causative agents is that some active infections are susceptible to specific treatment (herpes, Cytomegalovirus, hepatitis, campylobacter, influenza, and human immunodeficiency virus).

• For a better serological scrutiny of arboviruses, it is recommended to use reverse transcription polymerase chain reaction techniques from day 0 to 7 and later immunoglobulin M determination; in regions where there are infections by other arboviruses and there may be immunological cross-reactions between arboviruses (dengue, Zika, mayaro, chikungunya, oropouche, and yellow fever), it is recommended to perform the neutralization technique by plate reduction to elucidate which is the arboviral agent involved.

• Pharmacological treatment should be initiated as soon as the suspicion of Guillain–Barré syndrome is established, with intravenous immunoglobulin or plasmapheresis, the main lines of treatment. In the same way, concomitant therapies such as physical therapies and neuromuscular rehabilitation. The functional and vital prognosis of the patient depends on the promptness of the diagnosis and the establishment of the treatment.

• Use scales of functionality such as Hugues, medical research council, Erasmus (EGOS-EGRIS), to define the degree of affectionate and its recovery after the treatment provided.

• Remember that the management of these patients must be multidisciplinary for a better resolution.

**Funding**
None.

**Conflict of Interest**
None declared.

**References**